Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Invested Capital (2016 - 2025)

ImmunityBio (IBRX) has disclosed Return on Invested Capital for 11 consecutive years, with 0.5% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Invested Capital changed N/A to 0.5% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.5%, a N/A change, with the full-year FY2025 number at 0.64%, changed N/A from a year prior.
  • Return on Invested Capital was 0.5% for Q4 2025 at ImmunityBio, down from 1.18% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 2.89% in Q1 2025 to a low of 0.5% in Q4 2025.
  • A 5-year average of 1.22% and a median of 1.02% in 2022 define the central range for Return on Invested Capital.
  • Peak YoY movement for Return on Invested Capital: plummeted -5483bps in 2021, then soared 232bps in 2025.
  • ImmunityBio's Return on Invested Capital stood at 1.55% in 2021, then rose by 1bps to 1.57% in 2022, then crashed by -52bps to 0.76% in 2023, then plummeted by -34bps to 0.51% in 2024, then decreased by -1bps to 0.5% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Return on Invested Capital are 0.5% (Q4 2025), 1.18% (Q2 2025), and 2.89% (Q1 2025).